Effects of coenzyme Q10 on paraxonase, total antioxidant capacity, malondialdehyde, hs-CRP, lipid profile and glycemic control in patients with type 2 diabetes

Phase 3

• Conditions: type 2 diabetes.; Non-insulin-dependent diabetes mellitus

• Registration Number: IRCT138806102394N1
• Lead Sponsor: Vice-chancellor for research, Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1- Patients with type 2 diabetes
2- Willing to participate
3- Duration of type 2 diabetes > 1 year
4- HbA1c<9%
5-TG<400 mg/dL

Exclusion criteria:

1-BMI>40
2- Past history of MI or stroke
3-Patients with any of the following conditions: liver disease, kidney disease, or thyroid disease
4-Supplement use for at least 8 weeks before intervention till the end of study
5- Treatment with warfarin
6-BP>160/90
7-Pregnancy and lactation
8-Compliance<70%
9-Change in type or dose of medication for at least 8 weeks before intervention till the end of study
10-Treatment with insulin

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Paraxonase. Timepoint: before intervention, 12 weeks after intervention. Method of measurement: spectrophotometry.;Total antioxidant capacity. Timepoint: before intervention, 12 weeks after intervention. Method of measurement: FRAP.;MDA. Timepoint: before intervention, 12 weeks after intervention. Method of measurement: spectrophotometry.;Hs-CRP. Timepoint: before intervention, 12 weeks after intervention. Method of measurement: turbidometry.;Triglyceride. Timepoint: before intervention, 12 weeks after intervention. Method of measurement: Gop-PAP.;TC. Timepoint: before intervention, 12 weeks after intervention. Method of measurement: enzymatic.;LDL. Timepoint: before intervention, 12 weeks after intervention. Method of measurement: Friedewald formula.;HDL. Timepoint: before intervention, 12 weeks after intervention. Method of measurement: precipitation.;HbA1c. Timepoint: before intervention, 12 weeks after intervention. Method of measurement: chromatography.

Secondary Outcome Measures

Name	Time	Method
Insuline. Timepoint: before intervaention, 12 weeks after intervention. Method of measurement: RIA.;FBS. Timepoint: before intervaention, 12 weeks after intervention. Method of measurement: enzymatic.